EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH

Xin Zhang, Qianming Bai, Yulin Wang, Zhengzeng Jiang, Jing Han, Cheng Xue, Kai Huang, Lijuan Luan, Xiaoyong Huang, Xiaowu Huang, Guoming Shi, Yingyong Hou und 1 weitere

Virchows Archiv · 2025-11 · 487 (5) · 1103-1115

DOI: 10.1007/s00428-025-04067-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virchows Archiv, online erschienen am 08.04.2025. Verfasst von Xin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fudan University Zhongshan Hospital, 180 Fenglin Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Receptor, Fibroblast Growth Factor, Type 2, Bile Duct Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality, National Key Clinical Specialty Discipline Construction Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangement benefit from targeted therapies, highlighting the need for reliable testing strategies to identify FGFR2 alterations. We assessed 226 iCCA cases using RNA-based NGS, DNA-based NGS, and break-apart FISH to evaluate the effectiveness of these methods in detecting FGFR2 fusion/rearrangement. The detection rates for FGFR2 fusion/rearrangement were 9.7% (22/226) for RNA-based NGS, 7.1% (16/226) for DNA-based NGS, and 10.2% (23/226) for FISH. Among the 26 FGFR2 fusion/rearrangement-positive cases identified by any method, only 15 (57.7%) were positive by all three techniques, yielding a concordance rate of 95.1% (215/226). RNA-based NGS confirmed oncogenic FGFR2 fusion in 81% (21/26) of positive cases and identified five novel oncogenic fusions. Thirty-five percent (6/17) of the partner genes were located on chromosome 10, with BICC1 being the most common fusion partner, while the rest were distributed across the other 9 chromosomes. FISH demonstrated a sensitivity of 95.2% and specificity of 98.5%, compared to oncogenic FGFR2 fusions confirmed by RNA-based NGS, while DNA-based NGS exhibited a sensitivity of 71.4% and specificity of 99.5%, identifying FGFR2 mutations in 4 cases. FGFR2-FISH positive cases displayed no significant heterogeneity in positive cell distribution. Oncogenic FGFR2 fusion/rearrangement was associated with small duct type iCCA, especially in cases with positive serum HBsAg and absent cholangiolocarcinoma components and peripheral liver steatosis. This study provides a comprehensive comparison of three assays for detecting FGFR2 fusion/rearrangement, along with clinicopathologic characterization of oncogenic FGFR2 fusion in iCCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaReceptor, Fibroblast Growth Factor, Type 2Bile Duct NeoplasmsHigh-Throughput Nucleotide SequencingIn Situ Hybridization, FluorescenceOncogene Proteins, FusionBiomarkers, TumorGene RearrangementHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

FGFR2CholangiolocarcinomaMolecular detectionTarget therapyTyrosine kinase

Substanzen

Receptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanOncogene Proteins, FusionBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Fudan University Zhongshan Hospital, 180 Fenglin Road, Shanghai, 200032, China.
  • Department of Pathology, Fudan University Shanghai Cancer Centre, 270 Dong'an Road, Shanghai, 200032, China.
  • Department of Oncology, Fudan University Shanghai Medical College, Shanghai, 200032, China.
  • Shanghai Epione Medlab Co., Ltd, 1158 Zhongxin Road, Shanghai, 201615, China.
  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Fudan University Zhongshan Hospital, 180 Fenglin Road, Shanghai, 200032, China.
  • Department of Pathology, Fudan University Zhongshan Hospital, 180 Fenglin Road, Shanghai, 200032, China. ji.yuan@zs-hospital.sh.cn.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Key Clinical Specialty Discipline Construction Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, X., Bai, Q., Wang, Y., Jiang, Z., Han, J., Xue, C., Huang, K., Luan, L., Huang, X., Huang, X., Shi, G., Hou, Y., & Ji, Y. (2025). FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH. Virchows Archiv, 487(5), 1103-1115. https://doi.org/10.1007/s00428-025-04067-9

Vancouver

Zhang X, Bai Q, Wang Y, Jiang Z, Han J, Xue C, et al. FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH. Virchows Archiv. 2025;487(5):1103-1115. doi:10.1007/s00428-025-04067-9

BibTeX
@article{Zhang2025,
  author = {Zhang, Xin and Bai, Qianming and Wang, Yulin and Jiang, Zhengzeng and Han, Jing and Xue, Cheng and Huang, Kai and Luan, Lijuan and Huang, Xiaoyong and Huang, Xiaowu and Shi, Guoming and Hou, Yingyong and Ji, Yuan},
  title = {FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH},
  journal = {Virchows Archiv},
  year = {2025},
  volume = {487},
  number = {5},
  pages = {1103--1115},
  doi = {10.1007/s00428-025-04067-9}
}
Kostenlos starten →